Skip to content

XBIO REPORT

FREE WEEKLY BIOTECH STOCK CATALYST REPORTS
CONTACT

Tag: Respiratory Medicine

October 14, 2026

New Hope on the Horizon: Bristol Myers Squibb Launches Phase 3 ALOFT Trial for IPF

NYSE: $BMY A New Frontier in Pulmonary Research The fight against Idiopathic Pulmonary Fibrosis (IPF), a progressive and chronic lung disease, has reached a significant milestone. Bristol Myers Squibb has officially announced the initiation of the Phase 3 ALOFT clinical trial, a critical step in evaluating the efficacy and safety of a potential new treatment:…

Clinical Trial

$BMY, Admilparant, ALOFT, Bristol Myers Squibb, clinical trials, Idiopathic Pulmonary Fibrosis, IPF, Phase 3 Trial, Respiratory Medicine
January 20, 2026

Orphai Therapeutics’ LAM-001 Study Chosen for Key Presentation at ATS 2026

Orphai Therapeutics has achieved a significant milestone this week with the announcement that their Phase 2a clinical trial data for LAM-001 will be presented orally at the prestigious American Thoracic Society (ATS) 2026 International Conference. This selection is a strong indicator of the potential importance of their findings within the respiratory medicine community. Understanding the…

Conferences

ATS 2026, clinical trials, LAM-001, Orphai Therapeutics, Respiratory Medicine

© XBioReport.com

Disclaimer: This site is for information only. Not investment advice.

Buy A Premium Report To Maximize Your Returns

The FREE bio tech stock catalyst report ONLY includes companies with catalysts within the current week. Often, this may not be enough time to capture the pre-catalyst stock price movements. For MAX RETURNS, buy a premium report below with longer outlooks, allowing you to discover earlier trade entries. Get positioned BEFORE a price move happens. Don’t miss out, maximize your return potential!

Choose your outlook window (each priced accordingly)

Get FREE Biotech Stock Catalyst Reports

Email